Form 4: Neumora Therapeutics Executive Sells Shares to Cover Tax Obligations

Daljit Singh Aurora, Chief Strategy Officer of Neumora Therapeutics, sold shares of common stock on February 18, 2025, to satisfy tax withholding obligations related to vesting restricted stock units.

Summary

• Daljit Singh Aurora, Chief Strategy Officer of Neumora Therapeutics, sold 8,565 shares of common stock on February 18, 2025.
• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on April 22, 2024.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $1.6751, with individual trades ranging from $1.66 to $1.705.
• Following the transaction, Aurora directly owns 88,935 shares and indirectly owns 114,703 shares through the Aurora Family Trust.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax purposes) by an executive, which is neither particularly positive nor negative. The use of a 10b5-1 plan suggests pre-planning and compliance.

Future Outlook

The Rule 10b5-1 trading plan suggests that similar sales may occur in the future to cover tax obligations related to vesting restricted stock units.

Industry Context

Sales of shares by company executives to cover tax obligations are a common practice and are often pre-planned using Rule 10b5-1 trading plans to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a common practice across the pharmaceutical and biotechnology industries.
• Companies like Pfizer, Johnson & Johnson, and Amgen often see similar filings from their executives related to stock option exercises and RSU vesting.
• The use of Rule 10b5-1 plans is a standard method for executives to manage these transactions while complying with insider trading regulations.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but the pre-planned nature of the transaction mitigates this risk.

Key Dates

Keywords

Neumora Therapeutics, Daljit Singh Aurora, Form 4, insider trading, stock sale, Rule 10b5-1, tax withholding, NMRA